|Bid||21.20 x 1000|
|Ask||60.00 x 800|
|Day's Range||26.48 - 27.90|
|52 Week Range||17.96 - 63.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.80|
Insiders who bought Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) stock in the last 12 months were richly rewarded last...
Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) shareholders will have a reason to smile today, with the analysts making...
Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries IRVINE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Rosemary A